Search

Your search keyword '"Eri Kawata"' showing total 96 results

Search Constraints

Start Over You searched for: Author "Eri Kawata" Remove constraint Author: "Eri Kawata"
96 results on '"Eri Kawata"'

Search Results

1. Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study

2. P654: ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT-FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY

3. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

4. Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy

5. Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry

6. Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma

7. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations

8. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia

9. Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms

10. Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review

11. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

12. Data from Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

13. Supplementary Fig. S1 from Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

14. Supplementary Figure Legends from Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

15. Supplementary Figure S3 from Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma

17. Supplementary Table S1 from Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma

18. Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1/FLT3-ITD Genotypes in Patients with Acute Myeloid Leukemia

19. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

20. KIR3DL1-HLA-Bw Status Predict Favourable Achievement of Treatment Free Remission in CML: Results from the POKSTIC Trial, a Multicentre Retrospective Observational Study

22. A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study

23. Splanchnic vein thrombosis: Clinical manifestations, risk factors, management, and outcomes

24. Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: A retrospective study

25. Clinical value of next‐generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome

26. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study

27. Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?

28. Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations

29. Quality of life of patients with hematological malignancies and factors affecting health state utility values

30. Watchful waiting is an Acceptable Treatment Option for Primary Ocular Adnexal Mucosa-associated Lymphoid Tissue Lymphoma: A Retrospective Study

31. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study

32. Author response for 'Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma'

33. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

34. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia

35. Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy

36. Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry

37. Investigating Erythrocytosis: Changing Practice Patterns in the Era of Molecular Diagnostics

38. A Prediction Rule to Guide JAK2 Testing in Patients with Suspected Polycythemia Vera

39. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma

40. Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era

41. IgA-mediated autoimmune hemolytic anemia

42. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma

43. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations

44. Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

45. Prognostic impact of low allelic ratio

46. High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif

47. Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

48. The Clinical Application of Oncomine Myeloid Next Generation Sequencing (NGS): Comparison of Cytogenetics and NGS in Patients with Suspected Myelodysplastic Syndrome

49. Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations

50. ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin

Catalog

Books, media, physical & digital resources